Introduction: At ASMS 2026, Chinese enterprises are carving out their own position on the global mass spectrometry landscape. This achievement reflects China's overall growth in capabilities across sectors such as high-end manufacturing, life sciences, and the information industry.
Often referred to as the "Olympics" of the global mass spectrometry field, ASMS (the American Society for Mass Spectrometry Annual Conference) has long been a frontier for showcasing cutting-edge technology and setting industry trends. At ASMS 2026, a powerful force from the East is making an undeniable impact. From the independent development of core components to disruptive innovations in complete system design, and from ensuring the precision required for critical laboratory operations to revolutionizing full-lifecycle instrument services, Chinese companies are presenting "Chinese solutions" in mass spectrometry technology to the world.
Among the many exhibitors, PURSPEC—a Chinese manufacturer specializing in the independent R&D and production of mass spectrometry systems—made a significant impression. The company showcased its Gemini dual linear ion trap miniature mass spectrometer and the Ω Navigator, a next-generation lipid analysis system, while also delivering two oral presentations and five poster sessions. The new Gemini system features a proprietary dual linear ion trap mass analyzer, offering high sensitivity, specificity, and stability, and enabling seamless tandem mass spectrometry analysis across multiple scan modes. In terms of performance, the Gemini supports a detection range of m/z 50–2,000 with ng/mL-level sensitivity; it is compatible with both in-trap and beam-type CID fragmentation modes, providing robust support for complex molecular structure elucidation. Even more impressive is the system's deep integration of in-situ ionization kit technology, which streamlines the workflow—sample loading, reagent application, and detection—into a single process, delivering results in as little as one minute. Its intelligent design eliminates the need for external gas sources and supports the analysis of microliter-to-nanoliter (pL–nL) scale samples, directly addressing key pain points in on-site testing and liberating applications such as peptide sequencing, rapid pesticide residue screening, and single-cell analysis from the constraints of traditional laboratories. Meanwhile, the new-generation Ω Navigator lipid analysis system achieves highly sensitive resolution of C=C double-bond positions in lipid molecules—down to the nanomolar (nM) level—by combining photochemical derivatization with mass spectrometry. Supported by a database of over 120,000 structural lipids and intelligent algorithms, the system enables "full-dimensional analysis," ranging from total composition to specific double-bond locations, thereby providing a crucial tool for investigating disease mechanisms and discovering drug targets.
Concurrently, ASPEC collaborated with universities, research institutions, and industry partners to present eight SICRIT-based posters and one nanoESI oral presentation. These showcased the company's latest advancements in ambient mass spectrometry and soft ionization technologies. Addressing real-world samples and complex scenarios, the applications covered rapid screening, flavor profiling, oral headspace analysis, complex food matrices, TCM origin authentication, chromatography-free quantitation, and data-driven differential analysis—underscoring ASPEC’s ongoing commitment to bringing mass spectrometry technology into real-world applications. If the mass spectrometer is the "heart," then a stable laboratory gas supply is the "lifeline." During the conference, Shanghai Xiwei (Booth #1100) showcased its flagship Y-PNN and Y-HNN dual-purity nitrogen generators, which serve as a "powerful oxygen tank" for mass spectrometers. Designed specifically to meet the collision gas requirements of tandem mass spectrometers, ion mobility mass spectrometers, and CAD detectors, these products are widely used in general analysis and high-throughput routine proteomics. These models innovatively integrate both PSA and membrane nitrogen generation technologies, capable of simultaneously outputting ultra-high purity nitrogen (99.999%) and standard purity nitrogen (99%). A single unit can perfectly replace the traditional combination of a standard nitrogen generator, nitrogen cylinders, and an ultra-high purity nitrogen generator, thereby freeing up valuable laboratory space for high-throughput instruments like LC-MS systems. Additionally, the X-series nitrogen generators—tailored for modern laboratories—feature an integrated under-bench design (under 70 cm in height) and are equipped with touchscreen monitoring and maintenance alerts. They effectively resolve the pain points associated with traditional gas cylinders—such as frequent replacement, large footprint, and cumbersome management—perfectly embodying the concept of "unleashing laboratory productivity." Instrument operation relies heavily on efficient sample pretreatment workflows. CDS Analytical, a subsidiary of LabTech, showcased the EmporeOmics 1000—an integrated platform for mass spectrometry (MS) sample pretreatment and analysis—at its booth. Designed to meet the demand for high-throughput analysis of complex biological samples, the system deeply integrates solid-phase extraction (SPE), automated sample cleanup, and MS workflows, aiming to enhance both pretreatment efficiency and data consistency in omics research. Through a modular design, the EmporeOmics 1000 achieves workflow automation and method standardization; this reduces human error and significantly boosts batch processing capacity, making it particularly suitable for cutting-edge applications such as proteomics, metabolomics, and multi-omics integration.
Beyond hardware innovation, Shanghai Yinzhi Scientific Instruments (Booth #1116) made its ASMS debut by presenting a distinct "Chinese solution": a full-lifecycle service model for mass spectrometry instruments. Centered on the concept of "laboratory instrument lifecycle services," the company showcased a comprehensive solution covering the reconfiguration of high-end pre-owned mass spectrometers, maintenance services, and asset management. High-end instruments on display—such as the Thermo Fisher Orbitrap Exploris 480 and SCIEX Triple Quad 6500+—had undergone 72 specialized tests and OEM-standard calibrations, restoring their performance to near-new levels and offering research institutions significant cost advantages. At the event, Yinzhi introduced the concept of "instrument health management," emphasizing the use of dedicated health records and end-to-end maintenance systems to maximize asset utilization. Backed by a team of engineers with OEM backgrounds, the company demonstrated global maintenance capabilities—featuring a 3-hour response time, 48-hour troubleshooting, and 7-day loaner unit support—and highlighted its "5D Assessment + Three-Tier Protection" relocation technology, which ensures the safety of data and performance during the transport of precision equipment. Additionally, the company’s proprietary "Dengchen" laboratory gas generators were showcased, demonstrating its robust capability to expand from services into proprietary product manufacturing. Thanks to its differentiated service model and engineering expertise, Yinzhi attracted interest from numerous international pharmaceutical companies and Contract Research Organizations (CROs) at ASMS, establishing itself as a key representative of Chinese laboratory service providers on the global mass spectrometry stage. Beijing Huawei Zhongyi (Booth #1220) engaged in in-depth exchanges with domestic and international experts and technical teams in the fields of mass spectrometry and multi-omics, focusing on cutting-edge research needs. Their technology portfolio centers on five core areas: sorting of single cells (including protein-secreting and rare cells), cellular energy metabolism analysis, high-throughput microdroplet generation and sorting, gene transfection, and in situ single-cell quantitative analysis in tissues. Key systems—such as the OneCell fully automated high-throughput single-cell visualization screening system, the Incyton multimodal in situ energy metabolism monitoring platform, and the TissueCytometry system for in situ single-cell spatial phenotyping and quantification—enable upstream processes like precise functional cell screening, dynamic pharmacodynamic and toxicological characterization, and in situ spatial phenotyping. By linking these with mass spectrometers, the company achieves precise proteomic and metabolomic analysis at both single-cell and cell-population levels, creating an integrated platform that spans from functional phenotype analysis to high-throughput molecular qualitative and quantitative analysis; this platform supports cutting-edge research in areas such as tumor immunology, drug toxicology and efficacy, and the molecular mapping of tissue microenvironments.
Furthermore, other Chinese enterprises demonstrated their multidimensional strategic presence at ASMS 2026: Calibra, a veteran in clinical mass spectrometry, is a driving force in transitioning mass spectrometry from the laboratory to the bedside by closely integrating the technology with precision medicine, clinical diagnostics, and LDT services; BoHui Innovation focused on engineering integration, showcasing exceptional craftsmanship in its compact benchtop CMS and chip-based ion source (NanoMate); Novogene leveraged its leadership in omics services and bioinformatics to showcase the Biomek series of automated workstations—aligning perfectly with the ASMS 2026 trend of "automation and AI-driven workflows" and serving as a key engine for enhancing throughput and standardization in omics analysis; and WuXi AppTec, acting as a global platform empowering pharmaceutical R&D, demonstrated the core applications of mass spectrometry across the entire new drug development (DMPK) value chain—from drug discovery to preclinical development—thereby deeply integrating the innovative capabilities of domestic mass spectrometry technology into the global innovative drug R&D ecosystem. On the stage of ASMS 2026, Chinese enterprises are carving out a significant position in the global mass spectrometry landscape, driven by keen insight into market pain points, bold exploration of technological frontiers, and unique business model innovations. This progress reflects China's rising overall strength in sectors such as high-end manufacturing, life sciences, and the information industry. Looking ahead, as AI, omics, and mass spectrometry technologies deeply converge—and as Chinese companies play an increasingly pivotal role in the global ecosystem—a profound transformation spanning from technology to services, led by the "Chinese mass spectrometry contingent," is just beginning.